HER2 and response to anthracycline-based neoadjuvant chemotherapy in breast cancer

Annals of Oncology

Volumn 22, Issue 6, 2011, Pages 1326-1331

  Yao, L ^a   Liu, Y ^b   Li, Z ^a   Ouyang, T ^a   Li, J ^a   Wang, T ^a   Fan, Z ^a   Fan, T ^a   Lin, B ^a   Xie, Y ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^b CANCER HOSPITAL   (China)

Author keywords

Anthracycline; Breast cancer; HER2; Neoadjuvant chemotherapy

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE; AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; LETROZOLE; PIRARUBICIN; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADULT; AGE DISTRIBUTION; ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER RELAPSE; CANCER SURVIVAL; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DRUG RESPONSE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; MULTIPLE CYCLE TREATMENT; PARTIAL MASTECTOMY; PREDICTION; PRIORITY JOURNAL; TUMOR VOLUME;

EID: 79957820567     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq612     Document Type: Article

References (31)

1. Fisher B, Bryant J, Wolmark N. et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998; 16: 2672-2685.
2. Rastogi P, Anderson SJ, Bear HD. et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008; 26: 778-785.
3. van der Hage JA, van de Velde CJ, Julien JP. et al. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 2001; 19: 4224-4237.
4. Gralow JR, Burstein HJ, Wood W. et al. Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol 2008; 26: 814-819.
5. Kuerer HM, Newman LA, Smith TL. et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999; 17: 460-469.
6. Guarneri V, Broglio K, Kau SW. et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 2006; 24: 1037-1044.
7. Liedtke C, Mazouni C, Hess KR. et al. Response to neoadjuvant therapy and longterm survival in patients with triple-negative breast cancer. J Clin Oncol 2008; 26: 1275-1281.
8. Sikov WM, Dizon DS, Strenger R. et al. Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown University Oncology Group Study. J Clin Oncol 2009; 27: 4693-4700.
9. Smith IC, Heys SD, Hutcheon AW. et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 2002; 20: 1456-1466.
10. Gianni L, Baselga J, Eiermann W. et al. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in operable breast cancer. J Clin Oncol 2009; 27: 2474-2481.
11. Untch M, Mobus V, Kuhn W. et al. Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer. J Clin Oncol 2009; 27: 2938-2945.
12. Chuthapisith S, Eremin JM, El-Sheemy M, Eremin O. Neoadjuvant chemotherapy in women with large and locally advanced breast cancer: chemoresistance and prediction of response to drug therapy. Surgeon 2006; 4: 211-219.
13. Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN. Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 2007; 608: 1-22.
14. Buzdar AU. Preoperative chemotherapy treatment of breast cancer-a review. Cancer 2007; 110: 2394-2407.
15. Romond EH, Perez EA, Bryant J. et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-1684.
16. Revillion F, Bonneterre J, Peyrat JP. ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer 1998; 34: 791-808.
17. Tubbs R, Barlow WE, Budd GT. et al. Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status. J Clin Oncol 2009; 27: 3881-3886.
18. Gennari A, Sormani MP, Pronzato P. et al. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J Natl Cancer Inst 2008; 100: 14-20.
19. Bartlett JM, Munro A, Cameron DA. et al. Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial. J Clin Oncol 2008; 26: 5027-5035.
20. Pritchard KI, Shepherd LE, O'Malley FP. et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 2006; 354: 2103-2111.
21. Petit T, Borel C, Ghnassia JP. et al. Chemotherapy response of breast cancer depends on HER-2 status and anthracycline dose intensity in the neoadjuvant setting. Clin Cancer Res 2001; 7: 1577-1581.
22. Di Leo A, Chan S, Paesmans M. et al. HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. Breast Cancer Res Treat 2004; 86: 197-206.
23. Bear HD, Anderson S, Brown A. et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2003; 21: 4165-4174.
24. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-1717.
25. Paik S, Bryant J, Park C. et al. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 1998; 90: 1361-1370.
26. Muss HB, Thor AD, Berry DA. et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994; 330: 1260-1266.
27. Pegram MD, Finn RS, Arzoo K. et al. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene 1997; 15: 537-547.
28. Slamon DJ, Press MF. Alterations in the TOP2A and HER2 genes: association with adjuvant anthracycline sensitivity in human breast cancers. J Natl Cancer Inst 2009; 101: 615-618.
29. Qi M, Li JF, Xie YT. et al. Weekly paclitaxel improved pathologic response of primary chemotherapy compared with standard 3 weeks schedule in primary breast cancer. Breast Cancer Res Treat 2010; 123: 197-202.
30. Litton JK, Gonzalez-Angulo AM, Warneke CL. et al. Relationship between obesity and pathologic response to neoadjuvant chemotherapy among women with operable breast cancer. J Clin Oncol 2008; 26: 4072-4077.
31. Colleoni M, Bagnardi V, Rotmensz N. et al. Increasing steroid hormone receptors expression defines breast cancer subtypes non responsive to preoperative chemotherapy. Breast Cancer Res Treat 2009; 116: 359-369.